Following the July meetings of GMMMG and CEGC, the following actions have been published to the GMMMG website.
- Updated Medical Management of Tobacco Dependency guidance – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- GM Community Covid19 Medicines Delivery Pathway for non-hospitalised adult patients – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- Updates to formulary and RAG list – https://gmmmg.nhs.uk/joint-formulary/gmmmg-formulary-chapters/ and https://gmmmg.nhs.uk/rag-category/adult/. Full details are available in the formulary change log available on the formulary page.
Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the formulary change log available on the formulary page.
Colleagues are asked to disseminate for implementation within your organisations.
Decisions with a financial impact are awaiting approval by the GM ICB Executive and will be published once approved. These include:
- Doxylamine / pyridoxine (Xonvea) – remove grey status and make a first choice option for nausea and vomiting in pregnancy.
- Fluocinolone for chronic diabetic macular oedema
- Etrasimod for ulcerative colitis – RED
- Ritlecitinib for alopecia areata – RED
- Commissioning statement: Prescribing of statins for the prevention of CVD in people living with HIV
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.